A double-blind, placebo-controlled trial of topiramate for pathological gambling

Heather A. Berlin, Ashley Braun, Daphne Simeon, Lorrin M. Koran, Marc N. Potenza, Susan L. McElroy, Timothy Fong, Stefano Pallanti, Eric Hollander

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives. Pathological gambling (PG) is an impulse control disorder characterized by recurrent gambling thoughts and behaviours that impair social functioning. Earlier studies suggested that topiramate may be effective in treating some impulse control disorders. We conducted the first randomized, controlled trial of topiramate in PG. Methods. PG patients were randomized to topiramate (N = 20) or placebo (N = 22) in this 14-week, double-blind, placebo-controlled, parallel-group trial. The primary outcome measure was change in the obsessions subscale of the Yale-Brown Obsessive-Compulsive Scale Modified for Pathological Gambling. Results. Mixed regression models (time [weeks] × treatment) revealed no significant treatment effect of topiramate on the primary or secondary outcome measures. The most statistically robust findings involved reducing the Barratt Impulsiveness Scale (BIS) total score and Motor and Non-Planning subscale scores, for which topiramate outperformed placebo at merely a trend level (P < 0.1). Conclusions. The observed trend in BIS score reductions may warrant further investigation to study whether topiramate reduces clinically important impulsivity in PG. Treatment studies with larger samples and less stringent exclusion criteria are needed to produce results that can be generalized to pathological gamblers in the community.

Original languageEnglish (US)
Pages (from-to)121-128
Number of pages8
JournalWorld Journal of Biological Psychiatry
Volume14
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

Gambling
Placebos
Disruptive, Impulse Control, and Conduct Disorders
Outcome Assessment (Health Care)
Obsessive Behavior
Impulsive Behavior
topiramate
Therapeutics
Randomized Controlled Trials

Keywords

  • Impulse control disorder
  • Impulsivity
  • Pathological gambling
  • Placebo-controlled
  • Topiramate

ASJC Scopus subject areas

  • Biological Psychiatry
  • Psychiatry and Mental health

Cite this

A double-blind, placebo-controlled trial of topiramate for pathological gambling. / Berlin, Heather A.; Braun, Ashley; Simeon, Daphne; Koran, Lorrin M.; Potenza, Marc N.; McElroy, Susan L.; Fong, Timothy; Pallanti, Stefano; Hollander, Eric.

In: World Journal of Biological Psychiatry, Vol. 14, No. 2, 03.2013, p. 121-128.

Research output: Contribution to journalArticle

Berlin, HA, Braun, A, Simeon, D, Koran, LM, Potenza, MN, McElroy, SL, Fong, T, Pallanti, S & Hollander, E 2013, 'A double-blind, placebo-controlled trial of topiramate for pathological gambling', World Journal of Biological Psychiatry, vol. 14, no. 2, pp. 121-128. https://doi.org/10.3109/15622975.2011.560964
Berlin, Heather A. ; Braun, Ashley ; Simeon, Daphne ; Koran, Lorrin M. ; Potenza, Marc N. ; McElroy, Susan L. ; Fong, Timothy ; Pallanti, Stefano ; Hollander, Eric. / A double-blind, placebo-controlled trial of topiramate for pathological gambling. In: World Journal of Biological Psychiatry. 2013 ; Vol. 14, No. 2. pp. 121-128.
@article{c47873189f6f49cfba0613480b6bec08,
title = "A double-blind, placebo-controlled trial of topiramate for pathological gambling",
abstract = "Objectives. Pathological gambling (PG) is an impulse control disorder characterized by recurrent gambling thoughts and behaviours that impair social functioning. Earlier studies suggested that topiramate may be effective in treating some impulse control disorders. We conducted the first randomized, controlled trial of topiramate in PG. Methods. PG patients were randomized to topiramate (N = 20) or placebo (N = 22) in this 14-week, double-blind, placebo-controlled, parallel-group trial. The primary outcome measure was change in the obsessions subscale of the Yale-Brown Obsessive-Compulsive Scale Modified for Pathological Gambling. Results. Mixed regression models (time [weeks] × treatment) revealed no significant treatment effect of topiramate on the primary or secondary outcome measures. The most statistically robust findings involved reducing the Barratt Impulsiveness Scale (BIS) total score and Motor and Non-Planning subscale scores, for which topiramate outperformed placebo at merely a trend level (P < 0.1). Conclusions. The observed trend in BIS score reductions may warrant further investigation to study whether topiramate reduces clinically important impulsivity in PG. Treatment studies with larger samples and less stringent exclusion criteria are needed to produce results that can be generalized to pathological gamblers in the community.",
keywords = "Impulse control disorder, Impulsivity, Pathological gambling, Placebo-controlled, Topiramate",
author = "Berlin, {Heather A.} and Ashley Braun and Daphne Simeon and Koran, {Lorrin M.} and Potenza, {Marc N.} and McElroy, {Susan L.} and Timothy Fong and Stefano Pallanti and Eric Hollander",
year = "2013",
month = "3",
doi = "10.3109/15622975.2011.560964",
language = "English (US)",
volume = "14",
pages = "121--128",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - A double-blind, placebo-controlled trial of topiramate for pathological gambling

AU - Berlin, Heather A.

AU - Braun, Ashley

AU - Simeon, Daphne

AU - Koran, Lorrin M.

AU - Potenza, Marc N.

AU - McElroy, Susan L.

AU - Fong, Timothy

AU - Pallanti, Stefano

AU - Hollander, Eric

PY - 2013/3

Y1 - 2013/3

N2 - Objectives. Pathological gambling (PG) is an impulse control disorder characterized by recurrent gambling thoughts and behaviours that impair social functioning. Earlier studies suggested that topiramate may be effective in treating some impulse control disorders. We conducted the first randomized, controlled trial of topiramate in PG. Methods. PG patients were randomized to topiramate (N = 20) or placebo (N = 22) in this 14-week, double-blind, placebo-controlled, parallel-group trial. The primary outcome measure was change in the obsessions subscale of the Yale-Brown Obsessive-Compulsive Scale Modified for Pathological Gambling. Results. Mixed regression models (time [weeks] × treatment) revealed no significant treatment effect of topiramate on the primary or secondary outcome measures. The most statistically robust findings involved reducing the Barratt Impulsiveness Scale (BIS) total score and Motor and Non-Planning subscale scores, for which topiramate outperformed placebo at merely a trend level (P < 0.1). Conclusions. The observed trend in BIS score reductions may warrant further investigation to study whether topiramate reduces clinically important impulsivity in PG. Treatment studies with larger samples and less stringent exclusion criteria are needed to produce results that can be generalized to pathological gamblers in the community.

AB - Objectives. Pathological gambling (PG) is an impulse control disorder characterized by recurrent gambling thoughts and behaviours that impair social functioning. Earlier studies suggested that topiramate may be effective in treating some impulse control disorders. We conducted the first randomized, controlled trial of topiramate in PG. Methods. PG patients were randomized to topiramate (N = 20) or placebo (N = 22) in this 14-week, double-blind, placebo-controlled, parallel-group trial. The primary outcome measure was change in the obsessions subscale of the Yale-Brown Obsessive-Compulsive Scale Modified for Pathological Gambling. Results. Mixed regression models (time [weeks] × treatment) revealed no significant treatment effect of topiramate on the primary or secondary outcome measures. The most statistically robust findings involved reducing the Barratt Impulsiveness Scale (BIS) total score and Motor and Non-Planning subscale scores, for which topiramate outperformed placebo at merely a trend level (P < 0.1). Conclusions. The observed trend in BIS score reductions may warrant further investigation to study whether topiramate reduces clinically important impulsivity in PG. Treatment studies with larger samples and less stringent exclusion criteria are needed to produce results that can be generalized to pathological gamblers in the community.

KW - Impulse control disorder

KW - Impulsivity

KW - Pathological gambling

KW - Placebo-controlled

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=84874890135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874890135&partnerID=8YFLogxK

U2 - 10.3109/15622975.2011.560964

DO - 10.3109/15622975.2011.560964

M3 - Article

C2 - 21486110

AN - SCOPUS:84874890135

VL - 14

SP - 121

EP - 128

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 2

ER -